Expert Network Best Practices, Part II: Interpreting the SEC’s Risk Alert on MNPI
14 July 2022
Foley Partner Jim Lundy will join an ACA Group panel of subject-matter experts to examine the U.S. Securities and Exchange Commission’s (SEC) Division of Examinations recent risk alert highlighting common deficiencies in material non-public information (MNPI) observed during examinations. The panelists will discuss why these deficiencies are so common and how your firm can avoid making the same mistakes.
Key learning objectives:
- Rules about the use of Expert Networks and other research
- Use of alternative data outlined in the risk alert
- Application of the SEC’s “shadow trading” theory
- How your advisors and vendors can help you comply
In addition to Jim Lundy, the speakers include:
- Carlo di Florio, Chief Services Officer, ACA Group
- Dan Campbell, Director, ACA Group
- Jason Howard, GC/CCO, Tegus
There is no charge to attend this webinar. To register, click here.
People
Related Insights
07 April 2025
Labor & Employment Law Perspectives
Appeals Court Says Disability Not Required in Order to Recover Back Pay for Violation of ADA’s Medical Inquiry and Examination Provisions
Most employers are aware that, under the Americans with Disabilities Act (ADA), disability-related inquiries and medical examinations of employees may only be required when such inquiries and examinations are “job-related and consistent with business necessity.”
07 April 2025
Labor & Employment Law Perspectives
Another Court Blocks DEI-Related Certification Requirement
On March 27, 2025, U.S. District Judge Matthew Kennelly of the United States District Court for the Northern District of Illinois issued a temporary restraining order prohibiting the Department of Labor (DOL) from enforcing certain provisions of Executive Orders 14173 (Ending Illegal Discrimination and Restoring Merit-Based Opportunity) and 14151 against Chicago Women in Trades, a domestic nonprofit that receives federal funding from the DOL.
07 April 2025
PharmaPatents
Jepson Claim Format Does Not Avoid Written Description Scrutiny
Current written description jurisprudence can make it difficult to obtain broad antibody patents, leading practitioners to explore alternative claiming strategies in an effort to bypass the limited scope afforded under the structure-function paradigm.